Malarone Junior (Proguanil Hydrochloride, Atovaquone)

The combination works by targeting two essential parasite pathways. Atovaquone inhibits mitochondrial electron transport, halting energy production, while proguanil is converted to cycloguanil, which blocks the parasite’s dihydrofolate reductase enzyme. This dual action produces a synergistic effect that stops parasite replication and clears infection.

The specific dose of Malarone Junior is determined by a qualified prescriber based on the child’s weight, age, indication (prevention or treatment), and regional resistance patterns. Healthcare professionals tailor the regimen to ensure optimal efficacy and safety.

Safety data for atovaquone/proguanil in pregnancy and lactation are limited. Use during pregnancy or while breastfeeding should only occur after a risk‑benefit assessment by a healthcare professional. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their physician.

To request Malarone Junior, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and necessary import documentation.

Malarone Junior offers a convenient chewable tablet that combines two mechanisms of action, providing higher efficacy against chloroquine‑resistant Plasmodium falciparum compared with older monotherapies such as chloroquine. Its safety profile is generally favourable, though cost and the need for strict adherence may differ from alternatives like artemisinin‑based combination therapies.

Malarone Junior should be stored at temperatures below 25 °C, in its original blister pack, protected from moisture and direct sunlight. Keep the tablets out of reach of children and avoid exposing them to excessive heat or humidity to maintain potency.

Malarone Junior is supplied as a chewable tablet. The tablet should be chewed thoroughly and swallowed with water, following the prescriber’s instructions regarding timing relative to meals. For prophylaxis, it is usually taken once daily; for treatment, the regimen may differ and must be prescribed by a qualified clinician.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction, hemolytic anemia (especially in G6PD‑deficient patients), severe hypersensitivity or anaphylaxis, and significant blood‑cell abnormalities. Patients should seek immediate medical attention if they notice rash, jaundice, dark urine, or unexplained bleeding.

Malarone Junior is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any tablet excipients. It should be used with caution in patients with severe renal impairment, known G6PD deficiency, or those taking medicines that have major interactions, such as rifampin or strong CYP2C8 inhibitors.